CARDIOVASCULAR JOURNAL OF AFRICA • Volume 25, No 1, January/February 2014
14
AFRICA
disease.
Clin Chem
2003; 49: 389–395.
18. Tangurek B, Ozer N, Sayar N,
et al
. The relationship between endothe-
lial nitric oxide synthase gene polymorphism (T-786C) and coronary
artery disease in the Turkish population.
Heart Vessels
2006;
21
:
285–290.
19. Nakayama M, Yasue H, Yoshimura M,
et al
. T-786C mutation in the 5
′
flanking region of the endothelial nitric oxide synthase gene is associ-
ated with myocardial infarction, especially without coronary organic
stenosis.
Am J Cardiol
2000;
86
: 628–634.
20. HamstenA, Wiman B, de Faire U, Blomback M. Increased plasma levels
of a rapid inhibitor of tissue plasminogen activator in young survivors
of myocardial infarction.
N Engl J Med
1985;
313
: 1557–1563.
21. Held C, Hjemdahl P, Rehnqvist N,
et al
. Haemostatic markers, inflam-
matory parameters and lipids in male and female patients in the Angina
Prognosis Study in Stockholm (APSIS). A comparison with healthy
controls.
J Intern Med
1997;
241
: 59–69.
22. Eriksson P, Kallin B, van’t Hooft FM, Ba’venholm P, Hamsten A. Allele
specific increase in basal transcription of the plasminogen-activator
inhibitor 1 gene is associated with myocardial infarction
. Proc Natl
Acad Sci USA
1995;
92
: 1851–1855.
23. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr,
Marble SJ. TIMI frame count: a quantitative method of assessing coro-
nary artery flow.
Circulation
1996;
93
: 879–888.
24. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA.
Recommendations for quantification of Doppler echocardiography: A
report from the Doppler Quantification Task Force of the Nomenclature
and Standards Committee of theAmerican Society of Echocardiography.
J Am Soc Echocardiogr
2002;
15
: 167–184.
25. Tiret L, Rigat B, Visvikis S,
et al
. Evidence, from combined segrega-
tion and linkage analysis, that a variant of the angiotensin I-converting
enzyme (ACE) gene controls plasma ACE levels.
Am J Hum Genet
1992;
51
: 197–205.
26. Raynolds MV, BristowMR, Bush EW,
et al
. Perryman MB.Angiotensin-
converting enzyme DD genotype in patients with ischaemic or idiopath-
ic dilated cardiomyopathy.
Lancet
1993;
342
: 1073–1075.
27. Harn HJ, Chang CY, Ho LI,
et al.
Evidence that polymorphism of
the angiotensin converting enzyme gene may be related to idiopathic
dilated cardiomyopathy in the Chinese population.
Biochem Mol Biol
Int
1995;
35
: 1175–1181.
28. Iwai N, Ohmichi N, Nakamura Y, Kinoshita M. DD genotype of the
angiotensin-converting enzyme gene is a risk factor for left ventricular
hypertrophy.
Circulation
1994;
90
: 2622–2628.
29. Castellano M, Muiesan ML, Rizzoni D,
et al
. Angiotensin converting
enzyme I/D polymorphism and arterial wall thickness in a general
population: the Vobarno Study.
Circulation
1995;
91
: 2721–2724.
30. Hosoi M, Nishizawa Y, Kogawa K,
et al
. Angiotensin-converting
enzyme gene polymorphism is associated with carotid arterial wall
thickness in non-insulin-dependent diabetic patients.
Circulation
1996;
94
: 704–707.
31. Kurtoglu N, Akcay A, Dindar I. Usefulness of oral dipyridamole
therapy for angiographic slow coronary artery flow.
Am J Cardiol
2001;
87
: 777–779.
32. Yalcin AA, Kalay N, Caglayan AO, Kayaalti F, Duran M, Ozdogru I,
et al
. The relationship between slow coronary flow and angiotensin
converting enzyme and ATIIR1 gene polymorphisms.
J Natl Med Assoc
2009;
101
: 40–45.
33. Van Hinsbergh VW, Kooistra T, van den Berg EA, Princen HM, Fiers
W, Emeis JJ. Tumor necrosis factor increases the production of plasmi-
nogen activator inhibitor in human endothelial cells
in vitro
and in rats
in vivo.
Blood
1998;
72
: 1467–1473.
34. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin
stimulates the synthesis of plasminogen activator inhibitor 1 by the
human hepatocellular cell line Hep G2.
Thromb Haemost
1998;
60
:
491–494.
35. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney
AM. The two allele sequences of a common polymorphism in the
promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond
differently to interleukin-1 in HepG2 cells.
J Biol Chem
1993;
268
:
10739–10745.
36. Meade TW, RuddockV, StirlingY, Chakrabarti R, Miller GJ. Fibrinolytic
activity, clotting factors, and long term incidence of ischaemic heart
disease in the Northwick Park Heart Study.
Lancet
1993;
342
: 1076–
1079.
37. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery
to its potential role in cell motility and disease.
Thromb Haemost
2005;
93
: 631–640.
38. Schneiderman J, Sawdey MS, Keeton MR,
et al.
Increase type 1 plas-
minogen activator inhibitor gene expression in atherosclerotic human
arteries.
Proc Natl Acad Sci
1992;
89
: 6998–7002.
39. Lima LM, Carvalho MD, Fonseca Neto CP, Garcia JC, Sousa MO.
PAI-1 4G/5G polymorphism and plasma levels association in patients
with coronary artery disease.
Arq Bras Cardiol
2011;
97
: 462–389.
40. Onalan O, Balta G, Oto A,
et al
. Plasminogen activator inhibitor-1
4G4G genotype is associated with myocardial infarction but not with
stable coronary artery disease.
J Thromb Thrombol
2008;
26
: 211–217.
41. Schneider DJ, Hayes M, Wadsworth M,
et al
. Attenuation of neointi-
mal vascular smooth muscle cellularity in atheroma by plasminogen
activator inhibitor type 1 (PAI-1).
J Histochem
Cytochem
2004;
52
:
1091–1099.
42. Redmond EM, Cullen JP, Cahill PA,
et al
. Endothelial cells inhibit flow
induced smooth muscle cell migration: role of plasminogen activator
inhibitor-1.
Circulation
2001;
103
: 597–603.
43. Quyyumi AA, Dakak N, Andrews NP,
et al
. Nitric oxide activity in the
human coronary circulation.
J Clin Invest
1995;
95
: 1747–1755.
44. Ohashi Y, Kawashima S, Hirata KI,
et al
. Hypotension and reduced
nitric-elicited vasorelaxation in transgenic mice overexpressing
endothelial nitric oxide synthase.
J Clin Invest
1998;
2
: 2061–2071.
45. Camsari A, Pekdemir H, Cicek D,
et al.
Endothelin-1 and nitric oxide
concentrations and their response to exercise in patients with slow coro-
nary flow.
Circ J
2003;
67
: 1022–1028.
46. Sezgin N, Barutcu I, Sezgin AT,
et al
. Plasmanitric oxide levels and its
role in slow coronary flow phenomenon.
Int Heart J
2005;
46
: 373–382.
47. Nurkalem Z, Tangurek B, Zencirci E,
et al
. Endothelial nitric oxide
synthase gene (T-786C) polymorphism in patients with slow coronary
flow.
Coron Artery Dis
2008;
19
: 85–88.
48. Yan RT, Anderson TJ, Charbonneau F, Title L, Verma S, Lonn E.
Relationship between carotid artery intima-media thickness and brachi-
al artery flow-mediated dilation in middle-aged healthy men
. J Am Coll
Cardiol
2005;
45
: 1980–1986.
49. Korkmaz H, Akbulut M, OzbayY, Koc M. The relation of intima-media
thickness with endothelial function and left ventricular mass index.
Anadolu Kardiyol Derg
2010;
10
: 220–225.
